Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021.
Int Immunol
; 33(10): 529-540, 2021 09 25.
Article
in English
| MEDLINE | ID: covidwho-1575943
ABSTRACT
Coronavirus disease 2019 (COVID-19) has caused millions of deaths, and serious consequences to public health, economies and societies. Rapid responses in vaccine development have taken place since the isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the release of the viral genome sequence. By 21 May 2021, 101 vaccines were under clinical trials, and published data were available for 18 of them. Clinical study results from some vaccines indicated good immunogenicity and acceptable reactogenicity. Here, we focus on these 18 vaccines that had published clinical data to dissect the induced humoral and cellular immune responses as well as their safety profiles and protection efficacy.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Immunity, Humoral
/
COVID-19 Vaccines
/
COVID-19
/
Immunity, Cellular
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Animals
/
Humans
Language:
English
Journal:
Int Immunol
Journal subject:
Allergy and Immunology
Year:
2021
Document Type:
Article
Affiliation country:
Intimm
Similar
MEDLINE
...
LILACS
LIS